351 Vor Bbiopharma 2022.10.05 Genevieve De Manio Photography Scaled Aspect Ratio 1200 384

Platform & Pipeline

We are developing a proprietary platform for the treatment of Acute Myeloid Leukemia and other blood cancers

There is potential to enable treatment-resistant Hematopoietic Cell Transplants (HCTs) that allow new, potentially curative targeted therapy opportunities for AML and other blood cancers.

Our Platform

Vor Bio is developing a new treatment platform based upon proven technologies in genome engineering, engineered Hematopoietic Stem Cell (eHSC) biology, and CAR-T cells that could change the standard of care for blood cancers.

Our Pipeline

Our pipeline demonstrates the strength and potential of our novel platform, with two clinical trials currently recruiting patients with relapsed/refractory AML.

Our Approach

We aim to protect the healthy cells, expose the cancer, and change the standard of care for HCTs.